Novo Nordisk creates new unit to ramp up use of artificial intelligence and digital tools in research

Pharmaceutical firm Novo Nordisk is establishing a new, global focus area, bringing AI and other digital tools to its research and early development. In time, the unit will employ ”several hundreds of people,” says the head of the unit.

Lars Fogh Iversen will lead Novo Nordisk's new unit dubbed Digital Science & Innovation | Photo: Novo Nordisk / PR

Digital opportunities will soon be playing a more active role in the research conducted by Denmark’s biggest pharmaceutical firm, Novo Nordisk, which is why the company is establishing a new, global focus area for this purpose.

According to Novo Nordisk, the unit will consist of ”several hundreds of people” and will work with data and and a string of digital tools, including artificial intelligence, in connection with the company’s research and development of new drug candidates.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs